Robert Dood

1.1k total citations
20 papers, 269 citations indexed

About

Robert Dood is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Oncology. According to data from OpenAlex, Robert Dood has authored 20 papers receiving a total of 269 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Obstetrics and Gynecology, 8 papers in Reproductive Medicine and 5 papers in Oncology. Recurrent topics in Robert Dood's work include Endometrial and Cervical Cancer Treatments (7 papers), Ovarian cancer diagnosis and treatment (6 papers) and Uterine Myomas and Treatments (3 papers). Robert Dood is often cited by papers focused on Endometrial and Cervical Cancer Treatments (7 papers), Ovarian cancer diagnosis and treatment (6 papers) and Uterine Myomas and Treatments (3 papers). Robert Dood collaborates with scholars based in United States, United Kingdom and China. Robert Dood's co-authors include Anil K. Sood, Lívia S. Eberlin, Jonathan H. Young, Jinsong Liu, Robert Tibshirani, Kshipra M. Gharpure, Liang Li, Marta Sans, Jialing Zhang and Robert L. Coleman and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Robert Dood

19 papers receiving 269 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Dood United States 8 89 72 66 65 63 20 269
Isabelle Farré France 5 80 0.9× 62 0.9× 35 0.5× 18 0.3× 62 1.0× 10 208
Chunqin Pan China 10 153 1.7× 54 0.8× 35 0.5× 24 0.4× 22 0.3× 14 276
Emmanuelle Malaurie France 7 78 0.9× 21 0.3× 76 1.2× 22 0.3× 56 0.9× 15 199
David L. Phelps United Kingdom 8 149 1.7× 108 1.5× 57 0.9× 9 0.1× 33 0.5× 14 299
E.A. Dubil United States 7 72 0.8× 5 0.1× 44 0.7× 123 1.9× 52 0.8× 12 241
Jeremy Ford United Kingdom 8 118 1.3× 104 1.4× 41 0.6× 9 0.1× 23 0.4× 11 246
Shuangwei Zou China 10 154 1.7× 6 0.1× 53 0.8× 106 1.6× 29 0.5× 20 302
Maria Lycke Sweden 8 90 1.0× 45 0.6× 29 0.4× 49 0.8× 145 2.3× 12 276
Josef Chovanec Czechia 9 74 0.8× 5 0.1× 86 1.3× 69 1.1× 90 1.4× 23 275
Xiaotian Ni China 6 74 0.8× 20 0.3× 14 0.2× 28 0.4× 6 0.1× 9 158

Countries citing papers authored by Robert Dood

Since Specialization
Citations

This map shows the geographic impact of Robert Dood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Dood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Dood more than expected).

Fields of papers citing papers by Robert Dood

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Dood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Dood. The network helps show where Robert Dood may publish in the future.

Co-authorship network of co-authors of Robert Dood

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Dood. A scholar is included among the top collaborators of Robert Dood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Dood. Robert Dood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bosquet, Jesús González, Andrew Polio, Erin George, et al.. (2025). Training, Validating, and Testing Machine Learning Prediction Models for Endometrial Cancer Recurrence. JCO Precision Oncology. 9(9). e2400859–e2400859.
2.
Dood, Robert, et al.. (2022). Mortality Patterns of Synchronous Uterine and Ovarian Cancers: A SEER Registry Analysis. Cancer Epidemiology Biomarkers & Prevention. 31(11). 2038–2045. 1 indexed citations
3.
Dood, Robert, Britton Trabert, Theresa L. Werner, David K. Gaffney, & Elke A. Jarboe. (2022). The time is now to start molecular subtyping high-intermediate and high-risk endometrial cancers. International Journal of Gynecological Cancer. 32(8). 1087–1088. 2 indexed citations
4.
Allshouse, Amanda A., Dana R. Canfield, Ann M. Bruno, et al.. (2022). Prophylactic Ureteral Stent Placement and Urinary Injury During Hysterectomy for Placenta Accreta Spectrum. Obstetrics and Gynecology. 140(5). 806–811. 24 indexed citations
5.
Huang, Tianyi, Mary K. Townsend, Robert Dood, Anil K. Sood, & Shelley S. Tworoger. (2021). Antihypertensive medication use and ovarian cancer survival. Gynecologic Oncology. 163(2). 342–347. 13 indexed citations
6.
Siedel, Jean, Kari L. Ring, Wei Hu, et al.. (2021). Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecologic Oncology. 160(3). 777–785. 26 indexed citations
7.
Wagner, Michael J., Yasmin A. Lyons, Jean Siedel, et al.. (2021). Combined VEGFR and MAPK pathway inhibition in angiosarcoma. Scientific Reports. 11(1). 9362–9362. 24 indexed citations
8.
Hansen, Jean M., Wen Hu, Robert Dood, et al.. (2020). Homologous recombination deficiency score testing in endometrial cancer. Gynecologic Oncology. 159. 225–225. 1 indexed citations
9.
Lara, Olivia D., Zhihui Wang, Sara Corvigno, et al.. (2019). Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Scientific Reports. 9(1). 17589–17589. 16 indexed citations
10.
Dood, Robert, Yang Zhao, Shannon D. Armbruster, et al.. (2018). Defining Survivorship Trajectories Across Patients With Solid Tumors. JAMA Oncology. 4(11). 1519–1519. 36 indexed citations
11.
Dood, Robert, Shannon D. Armbruster, Shelley S. Tworoger, et al.. (2018). Defining survivorship and surveillance with evidence.. Journal of Clinical Oncology. 36(15_suppl). 6528–6528. 1 indexed citations
12.
Dood, Robert, Nicole D. Fleming, Robert L. Coleman, et al.. (2018). When Ovarian Cancer Is Not. International Journal of Gynecological Cancer. 28(8). 1485–1490. 3 indexed citations
13.
Sans, Marta, Kshipra M. Gharpure, Robert Tibshirani, et al.. (2017). Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. Cancer Research. 77(11). 2903–2913. 97 indexed citations
14.
Bottsford-Miller, Justin, Monika Haemmerle, Michael J. Wagner, et al.. (2017). Aspirin-PC is a novel, safe and efficacious compound in ovarian cancer. Gynecologic Oncology. 145. 85–86. 1 indexed citations
15.
Lyons, Yasmin A., Sunila Pradeep, Jean M. Hansen, et al.. (2017). Abstract 788: Less is more: macrophage depletion via CSF1/CSF1R pathway improves anti-VEGF therapy after adaptive resistance. Cancer Research. 77(13_Supplement). 788–788. 1 indexed citations
16.
Dood, Robert, Nicole D. Fleming, Robert L. Coleman, Shannon N. Westin, & Anil K. Sood. (2017). When advanced ovarian cancer is not ovarian cancer.. Journal of Clinical Oncology. 35(15_suppl). e17066–e17066. 1 indexed citations
17.
Dood, Robert, Larissa A. Meyer, Javier Lasala, et al.. (2017). Return to intended oncologic therapy (RIOT) after surgery for gynecologic cancer in an enhanced recovery after surgery (ERAS) program. Clinical Nutrition ESPEN. 19. 86–86. 3 indexed citations
18.
Dood, Robert, Archana S. Nagaraja, Yasmin A. Lyons, et al.. (2017). Knocking out stress: A systems-based identification of optimal drug combinations to improve ovarian cancer outcomes. Gynecologic Oncology. 145. 15–15. 1 indexed citations
19.
Dood, Robert, Kevin Haynes, & Emily Ko. (2016). Risk factors for surgical treatment delay in women with endometrial cancer. Gynecologic Oncology. 141. 37–37. 1 indexed citations
20.
Dood, Robert, Clarisa R. Gracia, Mary D. Sammel, et al.. (2014). Endometrial Cancer After Endometrial Ablation vs Medical Management of Abnormal Uterine Bleeding. Journal of Minimally Invasive Gynecology. 21(5). 744–752. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Isabelle Farré Breakdown of academic impact, for papers by Chunqin Pan Breakdown of academic impact, for papers by Emmanuelle Malaurie Breakdown of academic impact, for papers by David L. Phelps Breakdown of academic impact, for papers by E.A. Dubil Breakdown of academic impact, for papers by Jeremy Ford Breakdown of academic impact, for papers by Shuangwei Zou Breakdown of academic impact, for papers by Maria Lycke Breakdown of academic impact, for papers by Josef Chovanec Breakdown of academic impact, for papers by Xiaotian Ni
Rankless by CCL
2026